Mott Frank E
Department of Thoracic Head Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX USA.
Oncol Ther. 2017;5(1):69-74. doi: 10.1007/s40487-016-0038-7. Epub 2017 Jan 5.
Patient reported outcomes (PROs) are commonly integrated into clinical trials for new cancer therapies or treatment modalities; however, beyond a cursory review during the registration process for a new drug, these important measures of patient satisfaction and cost-effectiveness are often under-used in daily practice. We cite literature under-scoring the value of PROs not only in clinical trials, but in practical decision making and how such metrics can help guide the oncologist and the patient in choosing the best and most cost-effective therapy for their cancer. This is especially critical with the advent of new immunotherapies that are proving to be therapeutically beneficial for many patients, but not all, and at substantial cost in terms of toxicities and financial impact.
患者报告的结局（PROs）通常被纳入新癌症治疗方法或治疗模式的临床试验中；然而，除了在新药注册过程中的粗略审查外，这些衡量患者满意度和成本效益的重要指标在日常实践中往往未得到充分利用。我们引用文献强调PROs不仅在临床试验中，而且在实际决策中的价值，以及这些指标如何帮助肿瘤学家和患者选择最适合且最具成本效益的癌症治疗方法。随着新免疫疗法的出现，这一点尤为关键，因为事实证明，新免疫疗法对许多患者有益，但并非对所有患者都如此，而且在毒性和经济影响方面成本高昂。
